How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,523 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

142. Pruritus

33 6.4.3 Glucocorticosteroids 33 6.4.4 Opioid receptor agonists and antagonists 34 6.4.5 Gabapentin and pregabalin 35 6.4.6 Antidepressants 36 6.4.7 Serotonin receptor antagonists 38 6.4.8 Thalidomide 39 6.4.9 Leukotriene receptor antagonists and TNFa antagonists 39 6.4.10 Cyclosporine, methotrexate, azathioprine and tacrolimus 40 6.4.11 Neurokinin receptor 1 antagonist 41 6.4.12 Biologics 42 6.4.13 Physical treatment modalities 43 6.5 Ultraviolet phototherapy 45 6.6 Treament in special (...) -receptor opioid antagonists such as nalmefene and naltrexone supports the hypothesis that opioid receptors and a high opioid tone influences ChP (Bergasa, Schmitt et al. 1998). 11 4.1.4 Pruritus in metabolic and endocrine diseases In endocrine disorders such as hyperthyroidism and diabetes mellitus, less than 10% of patients report pruritus (Neilly, Martin et al. 1986, Jabbour 2003). In patients with hypothyroidism, pruritus is most probably driven by xerosis of the skin. Patients with primary

2019 European Dermatology Forum

143. Treatment for Acute Pain: An Evidence Map

several classes. Pain relieving analgesics include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen. These are often used in combination. Based on putative pain mechanisms, providers may also manage acute pain with muscle relaxants, antidepressants, alpha-2 agonists, GABA analogues, corticosteroids, NMDA receptor antagonists, local anesthetics, cannabinoids, among others. 23, 24 Topical agents such as capsaicin and lidocaine are also used. 23 Many medications for pain

2019 Effective Health Care Program (AHRQ)

144. Chronic Pelvic Pain

urinary tract. J Urol, 1998. 159: 2185. 170. Parsons, C.L., et al. Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. J Urol, 2000. 164: 1381. 171. Chelimsky, G., et al. Autonomic Testing in Women with Chronic Pelvic Pain. J Urol, 2016. 196: 429. 172. Charrua, A., et al. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourol Urodyn, 2015. 34: 489. 173

2019 European Association of Urology

146. Urolithiasis

., et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ, 2016. 355: i6112. 106. Guercio, S., et al. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. J Endourol, 2011. 25: 1137. 107. Ramsey, S., et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol, 2010. 24: 185. 108. Lynch, M.F., et (...) , 1994. 152: 1095. 114. Porpiglia, F., et al. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology, 2000. 56: 579. 115. Dellabella, M., et al. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology, 2005. 66: 712. 116. Campschroer, T., et al. Alpha-blockers as medical expulsive therapy

2019 European Association of Urology

147. Male Sexual Dysfunction

Hypertens, 2004. 17: 1135. 199. Kloner, R.A., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol, 2004. 172: 1935. 200. McCullough, A.R., et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology, 2002. 60: 28. 201. Forgue, S.T., et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol, 2006. 61: 280. 202. Nichols, D.J (...) with injection therapy: long-term dropout parameters. J Urol, 2000. 163: 467. 251. Buvat, J., et al. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol, 1998. 159: 116. 252. Mulhall, J.P., et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol, 1997. 158: 1752. 253. Bechara, A., et al. Comparative study of papaverine plus

2019 European Association of Urology

148. Management of Non-neurogenic Male LUTS

-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 2006. 147 Suppl 2: S88. 132. Kortmann, B.B., et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology, 2003. 62: 1. 133. Barendrecht, M.M., et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn, 2008. 27: 226. 134. Djavan, B., et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor (...) enlargement: 2-year results from the CombAT study. J Urol, 2008. 179: 616. 140. Roehrborn, C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010. 57: 123. 141. Nickel, J.C., et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract, 2008

2019 European Association of Urology

150. Canadian Cardiovascular Society Guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery

-bloqueurs dans les 24 heures qui pr ecèdent l’in- tervention chirurgicale; 5) la suspension des inhibiteurs de l’enzyme de conversion de l’angiotensine et des antagonistes des r ecepteurs de l’angiotensine II 24 heures avant l’intervention chirurgicale; 6) la facilitation de l’abandon du tabac avant l’intervention chirurgicale; 7) la mesure quotidienne de la troponine de 48 à 72 heures après l’in- terventionchirurgicalechezlespatientsquiavaientunemesure elev ee desNT-proBNP

2017 CPG Infobase

151. Choice of therapy for Adults With Hypertension Without Compelling Indications for Specific Agents

supporting use of beta-adrenergic antagonists (β-blockers) in this age group consists of four trials including the placebo-controlled Medical Research Council on Mild Hypertension trial , comparing thiazides with β-blockers, which failed cumulatively to detect any significant difference in occurrence of cardiovascular endpoints (RR, 0.95; 95%CI, 0.82 to 1.11), although number of events in these trials was insufficient to prove equivalence, thus justifying a Grade B rating . Additionally, β-blockers may (...) be noted that LIFE used a control regimen with suboptimal efficacy in older patients with hypertension (i.e., β-blockers) . However, data from the ONTARGET Trial supports the equivalence of ARBs to ACE inhibitors in high-risk patients and is the basis of the caution not to combine ACE and ARB therapy given the unfavourable risk benefit profile demonstrated . Alpha-blockers Alpha-blockers were inferior to diuretics in the ALLHAT trial and this resulted in early termination of the alpha-blocker arm

2018 Hypertension Canada

152. Treatment of Hypertension in Association With Left Ventricular Hypertrophy

with a decrease in left ventricular mass index of 13.3% (95%CI, 9.9%–16.8%), calcium channel blockers (CCBs) 9.3% (95%CI, 5.5%–13.1%), diuretics 6.8% (95%CI, 3.0%–10.7%) and beta-adrenergic antagonists (β-blockers) 5.5% (95%CI, 2.3%–8.6%) . However, this meta-analysis was small (1200 patients received active treatment; 189 received placebo), and mean duration of therapy was only 25 weeks. Subsequent studies have shown similar degrees of LVH regression with other agents, including alpha-blockers (ɑ-blockers (...) . Langenfeld MR, Gatzka CD, Weidinger G, Schobel HP. Impact of alpha- versus beta-blockers on hypertensive target organ damage: results of a double-blind, randomized, controlled clinical trial. Am J Hypertens 1997;10:985-91. Thurmann PA, Kenedi P, Schmidt H, Rietbrock N. Influence of the Angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42. Tedesco MA, Ratti G, Aquino D, et al. Effects of losartan on hypertension and left

2018 Hypertension Canada

153. Diagnosis & Assessment of Hypertension - Endocrine Hypertension

these conversion values with their local laboratories. Uncorrected hypokalemia (K + <3.3mmol/L), severe sodium restriction, and administration of renin-angiotensin inhibitors, diuretics and DHP-calcium channel antagonists may cause false-negative ratios and beta-blockers can cause a false positive . Other factors that can interfere with interpretation include renal dysfunction, oral contraceptives, NSAIDs, and in particular mineralocorticoid receptor antagonists. If possible, alpha blockers, hydralazine (...) adrenal adenoma, idiopathic hyperaldosteronism/bilateral adrenal hyperplasia, unilateral hyperplasia, and less commonly adrenal carcinoma and familial hyperaldosteronism (glucocorticoid remediable or non-remediable). Differentiation between unilateral and bilateral forms of aldosterone hypersecretion has important treatment implications. Unilateral forms might be amenable to improvement or even cure with adrenalectomy. In contrast, mineralocorticoid receptor antagonists are the treatment of choice

2018 Hypertension Canada

155. Gastroesophageal Reflux Disease (GERD) - Guidelines for Prescribing H2RAs and PPIs

, hypercalcemia Use of medications which reduce lower esophageal pressure can induce or worsen GERD – alpha-adrenergic antagonists, anticholinergics, beta-agonists, benzodiazepines (diazepam), calcium channel blockers (nifedipine, felodipine, amlodipine), nicotine, progesterone, theophylline For more information go to: CTC - Gastroesophageal Reflux - Available at . American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Available online at GERD (...) -The-Counter Drug Options Antacids, alginates; over-the-counter dose H2 receptor antagonists (H2RAs); OTC-dose H2RAs/alginate combination mild, infrequent symptoms Esomeprazole 20 mg or omeprazole 20 mg (14 days) mild and frequent symptoms (if daily treatment is preferred) or moderate symptoms. PPIs are considered first line. Grade A recommendation (consistent high-quality evidence) on-demand therapy for recurrent symptoms appearing 3 months after resolution of last episode esomeprazole or omeprazole

2018 medSask

156. Heart Failure Full Text available with Trip Pro

congestion on physical examination to decrease mortality and decrease hospitalisation. a Specifically, bisoprolol, carvedilol, metoprolol (controlled release or extended release) or nebivolol Weak FOR Low Mineralocorticoid receptor antagonists (MRAs) An MRA is recommended in all patients with HFrEF associated with a moderate or severe reduction in LVEF (LVEF less than or equal to 40%) unless contraindicated or not tolerated, to decrease mortality and decrease hospitalisation for heart failure. Strong (...) FOR High Mineralocorticoid receptor antagonists (MRAs) An MRA may be considered in patients with HFrEF associated with a mild reduction in LVEF (LVEF 41–49%) unless contraindicated or not tolerated, to decrease mortality and decrease hospitalisation for heart failure. Weak FOR Low Diuretics A diuretic should be considered in patients with heart failure and clinical symptoms, or signs of congestion, to improve symptoms and manage congestion. Strong FOR Very low Angiotensin receptor blockers (ARBs

2018 Cardiac Society of Australia and New Zealand

157. Urolithiasis

., et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ, 2016. 355: i6112. 106. Guercio, S., et al. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. J Endourol, 2011. 25: 1137. 107. Ramsey, S., et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol, 2010. 24: 185. 108. Lynch, M.F., et (...) , 1994. 152: 1095. 114. Porpiglia, F., et al. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology, 2000. 56: 579. 115. Dellabella, M., et al. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology, 2005. 66: 712. 116. Campschroer, T., et al. Alpha-blockers as medical expulsive therapy

2018 European Association of Urology

159. Male Sexual Dysfunction

Hypertens, 2004. 17: 1135. 199. Kloner, R.A., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol, 2004. 172: 1935. 200. McCullough, A.R., et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology, 2002. 60: 28. 201. Forgue, S.T., et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol, 2006. 61: 280. 202. Nichols, D.J (...) with injection therapy: long-term dropout parameters. J Urol, 2000. 163: 467. 251. Buvat, J., et al. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol, 1998. 159: 116. 252. Mulhall, J.P., et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol, 1997. 158: 1752. 253. Bechara, A., et al. Comparative study of papaverine plus

2018 European Association of Urology

160. Management of Non-neurogenic Male LUTS

-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 2006. 147 Suppl 2: S88. 132. Kortmann, B.B., et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology, 2003. 62: 1. 133. Barendrecht, M.M., et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn, 2008. 27: 226. 134. Djavan, B., et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor (...) enlargement: 2-year results from the CombAT study. J Urol, 2008. 179: 616. 140. Roehrborn, C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010. 57: 123. 141. Nickel, J.C., et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract, 2008

2018 European Association of Urology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>